Brokerages Set ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) PT at $77.00

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) has earned an average recommendation of “Moderate Buy” from the six research firms that are covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $77.00.

Several research firms have recently weighed in on ANIP. StockNews.com downgraded shares of ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, September 7th. Truist Financial reiterated a “hold” rating and set a $60.00 price objective (down from $80.00) on shares of ANI Pharmaceuticals in a research report on Wednesday, September 11th. Raymond James increased their target price on ANI Pharmaceuticals from $81.00 to $83.00 and gave the company an “outperform” rating in a report on Wednesday, September 18th. Piper Sandler assumed coverage on ANI Pharmaceuticals in a research report on Friday, October 11th. They issued an “overweight” rating and a $68.00 target price for the company. Finally, HC Wainwright reissued a “buy” rating and set a $94.00 price target on shares of ANI Pharmaceuticals in a research report on Tuesday, September 17th.

Hedge Funds Weigh In On ANI Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of the stock. Texas Permanent School Fund Corp raised its holdings in shares of ANI Pharmaceuticals by 1.3% during the first quarter. Texas Permanent School Fund Corp now owns 13,194 shares of the specialty pharmaceutical company’s stock worth $912,000 after acquiring an additional 172 shares in the last quarter. Louisiana State Employees Retirement System raised its stake in shares of ANI Pharmaceuticals by 2.7% during the 2nd quarter. Louisiana State Employees Retirement System now owns 7,700 shares of the specialty pharmaceutical company’s stock worth $490,000 after purchasing an additional 200 shares in the last quarter. Arizona State Retirement System raised its stake in shares of ANI Pharmaceuticals by 4.7% during the 2nd quarter. Arizona State Retirement System now owns 4,702 shares of the specialty pharmaceutical company’s stock worth $299,000 after purchasing an additional 211 shares in the last quarter. Simplicity Wealth LLC lifted its holdings in shares of ANI Pharmaceuticals by 3.5% during the 2nd quarter. Simplicity Wealth LLC now owns 6,733 shares of the specialty pharmaceutical company’s stock valued at $429,000 after buying an additional 227 shares during the last quarter. Finally, California State Teachers Retirement System grew its stake in shares of ANI Pharmaceuticals by 1.5% in the 1st quarter. California State Teachers Retirement System now owns 16,175 shares of the specialty pharmaceutical company’s stock valued at $1,118,000 after buying an additional 233 shares in the last quarter. 76.05% of the stock is currently owned by hedge funds and other institutional investors.

ANI Pharmaceuticals Trading Up 0.8 %

ANI Pharmaceuticals stock opened at $60.12 on Friday. ANI Pharmaceuticals has a 1 year low of $48.20 and a 1 year high of $70.81. The firm’s 50 day moving average price is $59.37 and its two-hundred day moving average price is $62.46. The firm has a market cap of $1.26 billion, a price-to-earnings ratio of 37.58 and a beta of 0.71. The company has a debt-to-equity ratio of 0.62, a quick ratio of 3.07 and a current ratio of 3.97.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its earnings results on Tuesday, August 6th. The specialty pharmaceutical company reported $1.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.95 by $0.07. ANI Pharmaceuticals had a return on equity of 15.64% and a net margin of 5.01%. The company had revenue of $138.00 million for the quarter, compared to analyst estimates of $129.09 million. During the same period in the previous year, the firm earned $1.06 earnings per share. ANI Pharmaceuticals’s revenue for the quarter was up 18.5% compared to the same quarter last year. On average, research analysts predict that ANI Pharmaceuticals will post 3.58 EPS for the current fiscal year.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.